

Friday March 27, 2026



## 2025 Annual Results Investor Call

### Dear Investors:

Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company's 2025 annual results, which will be held 10:30 AM HKT, March 27, 2026 (Friday).

During the conference call, management will provide a review of the Company's 2025 annual results, business updates, as well as address plans for the future.

### Details of the earnings call are as follows:

<b>Date:</b>	March 27, 2026
<b>Time:</b>	Login starts: 10:15AM HKT Meeting starts: 10:30AM
<b>Duration:</b>	Approximately 60mins (including Q&A session)
<b>Language:</b>	English
<b>Management:</b>	Dr. Li Chen, Founder and CEO George Lin, EVP & Chief Strategy Officer
<b>Moderator :</b>	Matthew Yan, CLSA Research Analyst
<b>RSVP:</b>	Please register in advance via this link: <a href="https://cls.a.zoom.com/meeting/register/KONtI003QBm9w-i6ymACBA">https://cls.a.zoom.com/meeting/register/KONtI003QBm9w-i6ymACBA</a> After registration, you will receive a confirmation email containing details about joining the zoom meeting

### About Hua Medicine

Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMISIS®, 華領片®) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.